{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:55Z","timestamp":1787020855317,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-026-07637-5","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:15:01Z","timestamp":1769195701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real world use of dalbavancin for bone and joint infections: a retrospective case series in adults and children"],"prefix":"10.1186","volume":"19","author":[{"given":"Preeti S.","family":"Ajapuje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samvveda","family":"Sameel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod S.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramprasad","family":"Dharangutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"12","key":"7637_CR1","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1086\/420939","volume":"38","author":"AD Tice","year":"2004","unstructured":"Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2004;38(12):1651\u201372.","journal-title":"Clin Infect Dis"},{"issue":"9431","key":"7637_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","volume":"364","author":"DP Lew","year":"2004","unstructured":"Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364(9431):369\u201379.","journal-title":"Lancet"},{"issue":"5","key":"7637_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/jac\/dks003","volume":"67","author":"AL Chapman","year":"2012","unstructured":"Chapman AL, Seaton RA, Kearns PJ, et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother. 2012;67(5):1053\u201362.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"7637_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2165\/00019053-200018050-00004","volume":"18","author":"AO Wai","year":"2000","unstructured":"Wai AO, Frighetto L, Marra CA, Chan E, Jewesson PJ. Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme: a Canadian teaching hospital and ministry of health perspective. Pharmacoeconomics. 2000;18(5):451\u20137.","journal-title":"Pharmacoeconomics"},{"issue":"15","key":"7637_CR5","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","volume":"298","author":"RM Klevens","year":"2007","unstructured":"Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the united States. JAMA. 2007;298(15):1763\u201371.","journal-title":"JAMA"},{"issue":"3","key":"7637_CR6","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u201355.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"7637_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/jac\/44.2.179","volume":"44","author":"G Candiani","year":"1999","unstructured":"Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F. In vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother. 1999;44(2):179\u201392.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"7637_CR8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","volume":"48","author":"A Leighton","year":"2004","unstructured":"Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(3):940\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"7637_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","volume":"51","author":"E Bouza","year":"2018","unstructured":"Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different Gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51(4):571\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"7637_CR10","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849\u201355.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"7637_CR11","doi-asserted-by":"crossref","first-page":"ofy114","DOI":"10.1093\/ofid\/ofy114","volume":"5","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Open Forum Infect Dis. 2018;5(6):ofy114.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"7637_CR12","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","volume":"47","author":"S Tobudic","year":"2019","unstructured":"Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with Dalbavancin therapy in Gram-positive skin and soft tissue infections, bone and joint infections. Infection. 2019;47(6):1013\u201320.","journal-title":"Infection"},{"key":"7637_CR13","first-page":"200","volume":"35","author":"C Lovatti","year":"2023","unstructured":"Lovatti C, et al. Dalbavancin in bone and joint infections: a systematic review of 20 studies and 450 patients. J Glob Antimicrob Resist. 2023;35:200\u20138.","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"7637_CR14","first-page":"106890","volume":"64","author":"P Alderson","year":"2024","unstructured":"Alderson P, et al. Real-world outcomes of Dalbavancin in bone and joint infections: a retrospective series of 58 cases. Int J Antimicrob Agents. 2024;64(2):106890.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"7637_CR15","doi-asserted-by":"publisher","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","volume":"6","author":"U Rappo","year":"2019","unstructured":"Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adults: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019;6(1):ofy331.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"7637_CR16","doi-asserted-by":"publisher","first-page":"e02280","DOI":"10.1128\/AAC.02280-18","volume":"63","author":"L Morata","year":"2019","unstructured":"Morata L, Cobo J, Fern\u00e1ndez-Sampedro M, et al. Safety and efficacy of prolonged use of Dalbavancin in bone and joint infections. Antimicrob Agents Chemother. 2019;63(5):e02280\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"7637_CR17","first-page":"75","volume":"10","author":"S Collier","year":"2025","unstructured":"Collier S, et al. Dalbavancin to facilitate early discharge in bone and joint infections: a multicentre analysis. J Bone Jt Infect. 2025;10(2):75\u201384.","journal-title":"J Bone Jt Infect"},{"issue":"2","key":"7637_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/idr14020032","volume":"14","author":"K Taylor","year":"2022","unstructured":"Taylor K, et al. Evaluating the use of Dalbavancin for off-label indications. Infect Dis Rep. 2022;14(2):266\u201372.","journal-title":"Infect Dis Rep"},{"key":"7637_CR19","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 31st ed. CLSI supplement M100. Wayne, PA: CLSI; 2021."},{"issue":"1","key":"7637_CR20","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/cid\/ciab884","volume":"75","author":"S Zhang","year":"2022","unstructured":"Zhang S, et al. Emergence of Dalbavancin resistance during therapy. Clin Infect Dis. 2022;75(1):e45\u20139.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"7637_CR21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cmi.2017.07.028","volume":"24","author":"BJ Werth","year":"2018","unstructured":"Werth BJ, et al. Emergence of Dalbavancin resistance in Staphylococcus aureus: clinical implications. Clin Microbiol Infect. 2018;24(4):431\u20134.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"7637_CR22","first-page":"1316","volume":"73","author":"HS Sader","year":"2018","unstructured":"Sader HS, Mendes RE, Streit JM, Flamm RK. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. J Antimicrob Chemother. 2018;73(5):1316\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"7637_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","volume":"8","author":"JT Bork","year":"2019","unstructured":"Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections. Infect Dis Ther. 2019;8(2):171\u201384.","journal-title":"Infect Dis Ther"},{"issue":"10","key":"7637_CR24","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1086\/497271","volume":"41","author":"LE Jauregui","year":"2005","unstructured":"Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407\u201315.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-026-07637-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07637-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07637-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:05:30Z","timestamp":1771434330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-026-07637-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7637"],"URL":"https:\/\/doi.org\/10.1186\/s13104-026-07637-5","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Ethics Committee (IEC) of Maeers Vishwaraj Hospital, Pune. The IEC is duly registered with the Central Drugs Standard Control Organization (CDSCO), Government of India (Registration No. ECR\/1138\/Inst\/MH\/2018\/RR-21). A waiver of informed consent was granted for this retrospective study. Due to the retrospective nature of this study, the institutional review board granted a waiver of informed consent in accordance with local ethics guidelines. All patient data were anonymized and handled in compliance with applicable privacy regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}